1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Isocitrate Dehydrogenase (IDH)

Isocitrate Dehydrogenase (IDH)

Isocitrate dehydrogenase (IDH) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producingalpha-ketoglutarate (α-ketoglutarate) and CO2. This is a two-step process, which involves oxidation of isocitrate (a secondary alcohol) to oxalosuccinate(a ketone), followed by the decarboxylation of the carboxyl group beta to the ketone, forming alpha-ketoglutarate. In humans, IDH exists in three isoforms: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. They localize to the cytosol as well as themitochondrion and peroxisome.

Isocitrate Dehydrogenase (IDH) Related Products (16):

Cat. No. Product Name Effect Purity
  • HY-18767
    Ivosidenib Inhibitor 98.72%
    Ivosidenib (AG-120) is a mutant isocitrate dehydrogenase 1 (IDH1) inhibitor with an IC50 of 12 nM for mouse IDH1R132H.
  • HY-18690
    Enasidenib Inhibitor 99.95%
    Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2R140Q and IDH2R172K, respectively.
  • HY-18082
    AGI-5198 Inhibitor 99.99%
    AGI-5198 is a potent and selective mutant IDH1R132H inhibitor with an IC50 of 0.07 μM.
  • HY-104042
    Vorasidenib Inhibitor 99.87%
    Vorasidenib is a pan isocitrate dehydrogenase (IDH) inhibitor.
  • HY-15734
    AGI-6780 Inhibitor 98.74%
    AGI-6780 that potently and selectively inhibits the tumor-associated mutant IDH2R140Q with IC50 of 23±1.7 nM. AGI-6780 is less potent against IDH2WT with IC50 of 190±8.1 nM.
  • HY-114226
    Olutasidenib Inhibitor
    Olutasidenib is a highly potent, selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1) that could be used in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
  • HY-112601
    IDH1 Inhibitor 1 Inhibitor
    IDH1 Inhibitor 1 is a potent, orally bioavailable, brain-penetrant and selective mutant IDH1 inhibitor with IC50s of 0.021 μM, 0.045 μM, and 2.52 μM for IDH1R132H, IDH1R132C, and IDH1WT, respectively. Anticancer activity.
  • HY-114459
    Mutant IDH1-IN-4 Inhibitor >99.0%
    Mutant IDH1-IN-4 (compound 434) is an inhibitor of mutant Isocitrate dehydrogenase 1 (IDH 1), with IC50 values of ≤ 0.5 μM for mutant IDH1 in R132H, HT1080 and U87R132H cells.
  • HY-19540
    GSK864 Inhibitor 99.36%
    GSK864 is an isocitrate dehydrogenase 1 (IDH1) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC50 values of 8.8, 15.2 and 16.6 nM.
  • HY-104036
    IDH-305 Inhibitor 98.01%
    IDH-305 is an inhibitor of isocitrate dehydrogenase (IDH).
  • HY-100020
    BAY-1436032 Inhibitor 98.94%
    BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.
  • HY-18767A
    (R,S)-Ivosidenib Inhibitor 98.61%
    (R,S)-Ivosidenib is a inhibitor of Isocitrate Dehydrogenase (IDH1).
  • HY-18690A
    Enasidenib mesylate Inhibitor 99.25%
    Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.
  • HY-13972
    Mutant IDH1 inhibitor Inhibitor 98.03%
    Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.
  • HY-18717
    Mutant IDH1-IN-2 Inhibitor
    Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.
  • HY-12475
    Mutant IDH1-IN-1 Inhibitor 99.60%
    Mutant IDH1-IN-1 is a mutant-selective IDH1 inhibitor with with IC50s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.